Wuxi AppTec CoWUXIF 81 EPS without NRI is $1.00 as of Mar. 2026. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $14.58 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 58.39% on this metric.
Wuxi AppTec Co's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $0.22.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $1.00.
During the past 12 months, Wuxi AppTec Co's average earnings per share (NRI) Growth Rate was 63.00% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 17.90% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 38.40% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 35.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Wuxi AppTec Co's EPS without NRI or its related term are showing as below:
WUXIF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 11.3 Med: 35.6 Max: 59.5
Current: 17.9
During the past 12 years, Wuxi AppTec Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 59.50% per year. The lowest was 11.30% per year. And the median was 35.60% per year.
WUXIF's 3-Year EPS without NRI Growth Rate is ranked better than 58.39% of 161
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.8
vs WUXIF: 17.90
Wuxi AppTec Co's EPS (Diluted) for the
three
months ended in Mar. 2026 was $0.23.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.98.
Wuxi AppTec Co's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.23.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.99.
Wuxi AppTec Co (OTCPK:WUXIF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Wuxi AppTec Co EPS without NRI Related Terms
Wuxi AppTec Co EPS without NRI Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, IDXX: EPS without NRI Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a EPS without NRI of $1.00 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Wuxi AppTec Co and its competitors. According to the industry distribution chart, Wuxi AppTec Co ranks #67 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 41.6%.
Is Wuxi AppTec Co's EPS without NRI too high?
Wuxi AppTec Co's current EPS without NRI is $1.00. The Medical Diagnostics & Research industry median EPS without NRI is 10.80. Wuxi AppTec Co's value of $1.00 is 90.7% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #67 out of 161 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #67 out of 161 companies for EPS without NRI. This puts Wuxi AppTec Co in the upper half of its industry. The industry median EPS without NRI is 10.80. Wuxi AppTec Co's value of $1.00 is 90.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current EPS without NRI of $1.00 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current EPS without NRI is $1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.58, compared to a current price of $21.19 — trading 45.3% above its estimated fair value. The current EPS without NRI is $1.00 and 90.7% below the Medical Diagnostics & Research industry median of 10.80. Wuxi AppTec Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current EPS without NRI is $1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $21.19 is trading 45.3% above its estimated GF Value™ of $14.58.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
EPS without NRI: $1.00
GF Value™: $14.58 vs. price of $21.19 (45.3% above fair value)
Industry Position: 90.7% below the Medical Diagnostics & Research median (#67 of 161)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
